advertisement
Hitzl W 20
Showing records 1 to 20 | Display all abstracts from Hitzl W109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Ayati N
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Huettenbrink C
World journal of urology 2023; 41: 1913-1919
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Lang R; Welponer T
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Schaldach J
World journal of urology 2023; 41: 1913-1919
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Jamshidi-Araghi Z; Hoellwerth M
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Hitzl W
World journal of urology 2023; 41: 1913-1919
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Richtig E; Wolf I
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Shamlou A
World journal of urology 2023; 41: 1913-1919
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Schweighofer-Zwink G
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Hoeller C
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Hitzl W
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Ell J
World journal of urology 2023; 41: 1913-1919
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Koelblinger P; Koelblinger P
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Hafner C
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109399 Different ureteral access sheaths sizes for retrograde intrarenal surgery
Pahernik S
World journal of urology 2023; 41: 1913-1919
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Nguyen VA
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Pirich C
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Kofler J
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810
109216 Predictive value and accuracy of FFDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
Beheshti M
European journal of nuclear medicine and molecular imaging 2023; 50: 2715-2726
109378 Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
Barta M; Koelblinger P; Koelblinger P; Hitzl W; Emberger M; Laimer M
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; 37: 1799-1810